| アブストラクト | OBJECTIVE: To describe reported cases of prolonged or relapsed ketoacidosis (KA) in adults with type 2 diabetes receiving treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors. METHODS: We performed a search of the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System and medical literature, to identify our case series and to characterize cases of prolonged KA, relapsed KA, or persistent ketonemia, persistent ketonuria and/or persistent glucosuria in adults receiving SGLT2 inhibitors. RESULTS: The FDA identified 29 unique cases of prolonged or relapsed KA, as well as related terms persistent ketonemia, persistent ketonuria, and persistent glucosuria, in patients receiving SGLT2 inhibitors through July 26, 2022. The patients ranged in age from 26 to 85 years. Treatment duration of KA ranged from 3 to 20 days. There were 7 cases of relapsed KA when insulin was reduced or transitioned to subcutaneous route. Arterial pH value was 7.0 or below in 4 patients, and the median pH was 7.1. Associated factors for prolonged or relapsed KA included surgery, decreased caloric intake, and ketogenic/carbohydrate restricted diet. A total of 62% of the patients were taking 3 or more glycemic control medications including the SGLT2 inhibitor. All patients with sufficient follow-up information recovered. CONCLUSION: Although KA is a well-known risk associated with SGLT2 inhibitors, this case series demonstrated the potential for prolonged or recurrent KA events with serious outcomes. These cases informed updates to FDA's prescribing information to inform prescribers of this risk. |
|---|
| ジャーナル名 | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists |
|---|
| Pubmed追加日 | 2024/5/2 |
|---|
| 投稿者 | Woronow, Daniel; Chamberlain, Christine; Houstoun, Monika; Munoz, Monica |
|---|
| 組織名 | Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center;for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver;Spring, Maryland. Electronic address: Daniel.Woronow@FDA.hhs.gov.;Spring, Maryland.;Division of Diabetes, Lipid Disorders, and Obesity, Office of New Drugs, Center |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38692489/ |
|---|
